<i>BRAF</i> V600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis
Aldo A. Acosta‐Medina, Paul G. Kemps, Timo C. E. Zondag, Jithma P. Abeykoon, Jelske Forma-Borst, Eline C. Steenwijk, Elizabeth A. M. Feijen, Jop C. Teepen, N. Nora Bennani, Susan Schram, Mithun Vinod Shah, Caroline Davidge‐Pitts, Matthew J. Koster, Jay H. Ryu, Robert Vassallo, W. Oliver Tobin, Jason R. Young, Surendra Dasari, Karen L. Rech, Aishwarya Ravindran, Arjen H.G. Cleven, Robert M. Verdijk, Carel J.M. van Noesel, Brian V. Balgobind, Gerrit J. Bouma, Peerooz Saeed, Jos A. M. Bramer, Ruben A. L. de Groen, Joost S.P. Vermaat, Michiel A. J. van de Sande, Egbert F. Smit, Anton W. Langerak, Tom van Wezel, Sanne H. Tonino, Cor van den Bos, Jan van Laar, Ronald S. Go, Gaurav Goyal, Astrid G. S. van Halteren
Abstract
In this retrospective study, BRAF mutation status did not correlate with disease extent or (event-free) survival in 156 adults with Langerhans cell histiocytosis. BRAFV600E was associated with an increased incidence of second malignancies, often comprising hematological cancers, which may be clonally related.